Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform

The Lancet Public Health, Journal Year: 2023, Volume and Issue: 8(5), P. e364 - e377

Published: April 27, 2023

Language: Английский

---

COVID-19 Severity and Mortality in Veterans with Chronic Lung Disease

Annals of the American Thoracic Society, Journal Year: 2024, Volume and Issue: 21(7), P. 1034 - 1043

Published: March 26, 2024

Chronic lung diseases (CLDs) have been variably associated with a risk for more severe manifestations and death coronavirus disease (COVID-19).

Language: Английский

---

Impact of Pulmonary Comorbidities on COVID-19: Acute and Long-Term Evaluations

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(5), P. 1446 - 1446

Published: Feb. 21, 2025

Background/Objectives: Pulmonary comorbidities, such as chronic obstructive pulmonary disease (COPD), asthma, and interstitial lung diseases (ILDs), have emerged critical factors influencing the severity outcomes of COVID-19. This review aims to evaluate interplay between these comorbidities COVID-19, both during acute phase in long-term recovery, focusing on their impact clinical management outcomes. Methods: systematic examined studies sourced from major medical databases, including PubMed Scopus, using keywords “COVID-19”, “pulmonary comorbidities”, “long COVID”, “respiratory sequelae”. Peer-reviewed articles published January 2020 present were included, with data extracted effects COVID-19 patients. Results: Patients COPD demonstrated significantly higher risks severe increased hospitalization mortality. Asthma, while less consistently associated outcomes, showed a variable risk based control. ILDs strongly correlated poor rates respiratory failure Long-term complications, persistent dyspnea, impaired function, structural changes like fibrosis, prevalent patients recovering moderate These complications adversely affected quality life healthcare dependency. Conclusions: amplify consequences Effective necessitates tailored strategies addressing phases, integrating rehabilitation continuous monitoring mitigate impairments. Future research should prioritize understanding mechanisms behind interactions inform public health interventions improve patient

Language: Английский

---

Healthcare utilization trends in adults with asthma or COPD during the first year of COVID-19 pandemic in comparison to pre-pandemic: A population-based study

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(3), P. e0316553 - e0316553

Published: March 6, 2025

To assess how changes in outpatient services during the first year of COVID-19 pandemic were related to acute healthcare use (emergency department or hospitalizations) for individuals with asthma chronic obstructive pulmonary disease (COPD). We conducted an observational study using health administrative data Ontario (Canada) from January 2016 March 2021 on all adults diagnosed COPD. used monthly time series auto-regressive integrated moving-average (ARIMA) and pre-pandemic rates (January February 2020) calculate projected (i.e., a had not occurred) (March 2020 2021), Quasi-Poisson models two-way interaction estimate crude adjusted rate ratios. In year, COPD, visit started lower than (Mar-May 2020), returned middle (Jun-Aug then rose higher between Sep Mar 2021: observed 80,293 per 100,000 persons vs. 74,192 (95% CI: 68,926-79,868) asthma, 92,651 85,871 79,975-92,207) Acute care remained below year. While function test (PFT) both populations, decrease visits pandemic, compared pre-pandemic, was noted months highest PFT (interaction p-values < 0.0001). Despite COPD being ambulatory-care sensitive conditions, beginning associated increased use. Lower rates, suggesting that access is likely important

Language: Английский

---

Outcomes among patients with chronic obstructive pulmonary disease after recovery from COVID-19 infection of different severity

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: June 16, 2024

Abstract While studies have suggested increased risks of severe COVID-19 infection in chronic obstructive pulmonary disease (COPD), the persistent and delayed consequences on patients with COPD upon recovery remain unknown. A prospective clinical study was conducted Hong Kong to investigate outcomes who had different severity (mild-moderate COVID-19), compared those did not. Chinese ≥ 40 years old were recruited from March September 2021. They prospectively followed up for 24.9 ± 5.0 months until 31st August 2023. The primary outcome deterioration control defined as change mMRC dyspnea scale. secondary included exacerbation frequency non-COVID-19 respiratory mortality (including death or bacterial pneumonia). 328 analysis. Patients mild-moderate statistically significant worsening dyspnoea scale by increase 1 score baseline follow-up adjusted odds ratios 4.44 (95% CI = 1.95–10.15, p < 0.001) 6.77 2.08–22.00, respectively. significantly 4.73 1.55–14.41, 0.006) pneumonia hazard ratio 11.25 2.98–42.45, 0.001). After COVID-19, dyspnea, (COPD pneumonia) observed among COVID-19. Mild moderate also associated symptomatic deterioration.

Language: Английский

---

COPD-Related Mortality before and after Mass COVID-19 Vaccination in Northern Italy

Vaccines, Journal Year: 2023, Volume and Issue: 11(8), P. 1392 - 1392

Published: Aug. 21, 2023

Background/Objective: Little is known about the impact of COVID-19 pandemic on mortality from COPD at population level. The objective was to investigate COPD-related throughout different epidemic waves in Italy before and after vaccination campaign, which started late December 2020 initially targeted aged ≥80 years. Methods: Death certificates residents Veneto (Northeastern Italy) ≥40 years between 2008 2021 were analyzed. Age-standardized morality rates computed for death with any mention COPD. Generalized estimating equation (GEE) models fitted estimate expected during pandemic. results stratified by age groups 40–79 years, main comorbidities, place death. Results: mentioned 3478 (+14% compared 2018–2019 average) 3133 (+3%). increased all sex 2020; 2021, returned pre-pandemic levels among elderly but not (+6%). GEE confirmed this differential trend age. peaks observed, especially first waves, identified as underlying cause a relevant proportion (up 35% November 2020–January 2021). Mortality comorbid diabetes hypertensive diseases slightly Conclusion: beginning pandemic, due deaths COVID-19. start campaign associated an important decline mortality, elderly, who benefited vaccines. study findings show role mass reducing later phases

Language: Английский

---

The Association of Asthma and Metabolic Dysfunction With Outcomes of Hospitalized Patients With COVID-19

The Journal of Allergy and Clinical Immunology In Practice, Journal Year: 2024, Volume and Issue: 12(9), P. 2390 - 2398.e7

Published: May 23, 2024

Language: Английский

---

Asthma and clinical outcomes of COVID-19 in a community setting

Public Health, Journal Year: 2023, Volume and Issue: 226, P. 84 - 90

Published: Nov. 27, 2023

Language: Английский

---

New score to predict COVID-19 progression in vaccine and early treatment era: the COVID-19 Sardinian Progression Score (CSPS)

European journal of medical research, Journal Year: 2024, Volume and Issue: 29(1)

Published: Feb. 15, 2024

Abstract Background Several scores aimed at predicting COVID-19 progression have been proposed. As the variables vaccination and early SARS-CoV-2 treatment were systematically excluded from prognostic scores, present study's objective was to develop a new model adapted current epidemiological scenario. Methods We included all patients evaluated by Infectious Disease Unit in Sassari, with infection without signs of respiratory failure first evaluation (P/F > 300). defined prescription supplemental oxygen. In addition, related demographics, vaccines, comorbidities, symptoms, CT scans, blood tests, therapies collected. Multivariate logistic regression modelling performed determine factors associated progression; any variable significant univariate test or clinical relevance selected as candidate for multivariate analysis. Hosmer–Lemeshow (HL) goodness fit statistic calculated. Odds ratio values used derive an integer score developing easy-to-use risk score. The discrimination performance index determined using AUC, best cut-off point, according Youden index, sensitivity, specificity, predictive value, likelihood ratio, chosen. Results 1145 [median (IQR) age 74 (62–83) years; 53.5% males] enrolled; 336 (29.3%) had disease progression. Patients older showed more comorbidities; furthermore, they less vaccinated exposed preventive therapy. analysis, ≥ 60 years, COPD, dementia, haematological tumours, heart failure, exposure no one vaccine dose, fever, dyspnoea, GGO, consolidation, ferritin, De Ritis 1.2, LDH, anti-SARS-CoV-2 final ranged 0 45. ROC curve analysis AUC 0.92 (95% CI 0.90–0.93) 93.7% specificity 72.9% sensitivity. Low when value than 23. Three levels identified: low (0–23 points), medium (24–35), high (≥ 36). Conclusions proportion increases scores: assessment could be helpful clinicians plan appropriate therapeutic strategies.

Language: Английский

---

Impact and prevalence of comorbidities and complications on the severity of COVID-19 in association with age, gender, obesity, and pre-existing smoking: A meta-analysis

Biomedicine, Journal Year: 2024, Volume and Issue: 14(1)

Published: Feb. 28, 2024

Background: COVID-19 patients usually present multiple comorbidities and complications associated with severe forms of SARS-CoV-2 infection. This study aimed to assess the risk factors prevalence contributing severity COVID-19.

Language: Английский

---